Neuroendocrine cancer aggressive

Conținutul

neuroendocrine cancer aggressive

Artikelempfehlungen Abstract The neuroendocrine tumors NETs are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy.

neuroendocrine cancer aggressive

Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile.

Material and Methods.

  • Ciuperci regionalisme
  • Papilloma on breast mri
  • Но не хочу говорить этого остальным.

  • Retete dezintoxicarea organismului

All the patients had at least one assay per year. The dose of octreotide varied from 20 to 50 mg, monthly.

The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered.

One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all the 9 cases, marking the disease progression.

MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography. Only one typical carcinoid presented the characteristic appearance of central endobronchial nodule with distal pulmonary atelectasis, while the others were pulmonary nodules or masses. The atypical carcinoids corresponded to peripheral heterogeneous masses. One out of the three LCNCs was a peripheral homogeneous mass, while the others were ill-defined and heterogeneous. The 11 SCLCs corresponded to central, infiltrating and heterogeneous masses with secondary pleuropulmonary changes.

The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.

Что, по-твоему, их ожидает. - спросила Наи.

Neuroendocrine tumors. Endocr Relat Cancer. DOI: Oberndorfer S. Karzinoide tumoren des dunndarms.

Frank Z Pathol. Carcinoid Tumors.

  1. В них не было ничего, кроме воды.

Bellizzi AM. Assigning site neuroendocrine cancer aggressive origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol. Chromogranins A B C: widespread consitituents of secretory vesicles.

neuroendocrine cancer aggressive

Ann N Y Acad Sci. Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.

CO; 8. Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.

Services on Demand

Neuroendocrine cancer aggressive dedifferentiation of neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med.

neuroendocrine cancer aggressive

Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol.

Кстати, ты успела поговорить с Патриком о Кэти. - Очень коротко, - ответила Николь вздыхая.

Long-term clinical outcome of somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol.

neuroendocrine cancer aggressive mam v tele parazity

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.